2 results
Not approvedWill not start
The primary objective is to evaluate health related QoL under an oral sequential treatment with natural steroid hormones: Duogestan®. The secondary objective is to evaluate the bleeding patterns over a one-year period.
Approved WMOWill not start
This study will evaluate the efficacy of brentuximab vedotin in combination with lenalidomide and rituximab among subjects with relapsed or refractory CD30-positive (CD30 expression >=1%) or CD30 <1% (CD30 expression <1%) DLBCL.